The innovation disclosed herein relates to microfluidic-chip technology and more specifically, microfluidic-chip technology for electromagnetic sensing of biomolecules and bioparticles.
Due to their large mass and “soft” hydrogen bonds, biomolecules and bioparticles can vibrate resonantly at much lower frequencies than smaller molecules, sometimes in the THz region of the electromagnetic spectrum. The challenge in measuring these resonances by radiative spectroscopy is their quality factor (Q) and their polarity. Because of the high absorption by liquid water at all frequencies below the infrared radiation waves, there is strong background attenuation in any aqueous biosample, which can mask the biomolecular resonance. Finally, assuming a resonant vibration with suitably weak damping, the molecule still has to have a net dipole moment (i.e., polarity) to interact with radiation. Some biomolecules (e.g., nucleic acids) have strong polarity in their physiological state, whereas others (e.g., polysaccharides) are less polar.
In measuring resonant signatures, sample preparation and presentation is very important, as is instrumentation. The samples to be detected often have very small volume or, if the volume is substantial, have very low biomolecular concentration. Therefore, it is very important that the sample holder operate with small biosample volumes and very efficient interaction between this volume and the interrogating electromagnetic radiation.
In addition, during the past several years, there has been an explosion of improvements in respiratory virus diagnostics, from novel specimen collection instruments to highly sensitive and multiplexed nucleic acid amplification tests. With the expanding list of antigen and molecular-based tests, it is now possible for laboratories to offer comprehensive testing for respiratory viruses without even performing virus isolation. Recent advances have also been made to this traditional approach to improve the turn-around time by using a combination of shell vial cultures and immunostaining.
Because of the sensitivity and rapid turn-around time, nucleic acid amplification technologies such as polymerase chain reaction (PCR) will likely be the focus of further advances in respiratory virus diagnostics. The future will likely promise additional commercial test kits for molecular detection of respiratory viruses, including multiplexed assays. Because of their exquisite sensitivity, nucleic acid amplification tests can create diagnostic conundrums. Additional research is needed to elucidate the clinical significance of positive PCR results that are persistent in a patient, and when two or more respiratory viruses are detected in a single specimen.
Future research on respiratory virus diagnostics should aim towards the ability to accurately detect a spectrum of clinically significant viruses rapidly enough to affect patient management and initiation of infection control measures while keeping the costs affordable. Commercial kits provide standardization not achievable with laboratory-developed tests, but at a substantially higher cost. Ultimately, the utilization of molecular testing, particularly highly multiplexed tests in routine patient management will depend on the cost/benefit ratio. Current and future diagnostic options will include antigen, molecular, and culture-based methods. The performance characteristics and limitations of these methods will vary greatly with the new generations of assays.
At present, the detection of viruses in human beings is carried out by indirect means, such as the measurement of antibodies in the blood, or by PCR. Antibodies are produced by the human body in response to viral maladies, and usually take the form of specific proteins. PCR is a biochemical technology in molecular biology used to amplify a single or a few copies of a piece of DNA across several orders of magnitude, generating thousands to millions of copies of a particular DNA sequence. In both cases there are problems with false positives.
The following presents a simplified summary in order to provide a basic understanding of some aspects of the innovation. This summary is not an extensive overview of the innovation. It is not intended to identify key/critical elements or to delineate the scope of the innovation. Its sole purpose is to present some concepts of the innovation in a simplified form as a prelude to the more detailed description that is presented later.
In an aspect of the innovation, a coplanar waveguide transmission line for use in detecting biomolecules and bioparticles is disclosed that includes a dielectric substrate, a signal conductor disposed on a top surface of the dielectric substrate, a ground conductor disposed on the top surface of the dielectric substrate on each side of the signal conductor, a continuous gap defined between the signal conductor and each of the ground conductors, a plurality of micro-channels disposed below a top surface of the dielectric substrate, and a plurality of reservoirs disposed below the top surface of the substrate, wherein the plurality of reservoirs supply an aqueous solution to the micro-channels.
In another aspect of the innovation a microfluidic bio-detection chip is disclosed that includes a dielectric substrate, a coplanar waveguide transmission line disposed on a top surface of the dielectric substrate, the coplanar waveguide transmission line including, a pad region, a microfluidic region, and a taper region connecting the pad region to the microfluidic region, a pair of continuous gaps extending along the coplanar waveguide transmission line, a microchannel region disposed below a top surface of the dielectric substrate, and a plurality of reservoirs disposed below the top surface of the substrate, wherein the plurality of reservoirs supply an aqueous solution to the microchannel region.
In yet another aspect of the innovation a method of detecting a virus is disclosed that includes providing a coplanar waveguide transmission line having a pad section, a taper section, and a microfluidic section, the microfluidic section being disposed above a microchannel region, generating an electric field in a pair of continuous gaps defined in the coplanar waveguide transmission line, coupling via the electric field the microfluidic region and the microchannel region, monitoring for a presence of an electromagnetic signature in a biosample, and detecting a presence of biomolecules and bioparticles.
To accomplish the foregoing and related ends, certain illustrative aspects of the innovation are described herein in connection with the following description and the annexed drawings. These aspects are indicative, however, of but a few of the various ways in which the principles of the innovation can be employed and the subject innovation is intended to include all such aspects and their equivalents. Other advantages and novel features of the innovation will become apparent from the following detailed description of the innovation when considered in conjunction with the drawings.
The innovation is now described with reference to the drawings, wherein like reference numerals are used to refer to like elements throughout. In the following description, for purposes of explanation, numerous specific details are set forth in order to provide a thorough understanding of the subject innovation. It may be evident, however, that the innovation can be practiced without these specific details. In other instances, well-known structures and devices are shown in block diagram form in order to facilitate describing the innovation.
While specific characteristics are described herein (e.g., thickness), it is to be understood that the features, functions and benefits of the innovation can employ characteristics that vary from those described herein. These alternatives are to be included within the scope of the innovation and claims appended hereto.
While, for purposes of simplicity of explanation, the one or more methodologies shown herein, e.g., in the form of a flow chart, are shown and described as a series of acts, it is to be understood and appreciated that the subject innovation is not limited by the order of acts, as some acts may, in accordance with the innovation, occur in a different order and/or concurrently with other acts from that shown and described herein. For example, those skilled in the art will understand and appreciate that a methodology could alternatively be represented as a series of interrelated states or events, such as in a state diagram. Moreover, not all illustrated acts may be required to implement a methodology in accordance with the innovation.
Disclosed herein is an innovative microfluidic bio-detection chip used to detect biomolecules and bioparticles in accordance with an aspect of the innovation. The innovation determines the presence of biomolecules or particles, such as proteins, nucleic acids, cytokines, viruses, and cells, by their unique electromagnetic signature. More specifically, as shown in the transmittance vs frequency graph 10 in
Referring to both
The CPW transmission-line 400 further includes a pair of pad regions (or signal/ground pad sections) 408, a pair of taper (condenser) regions (or signal/ground taper sections) 410, and a microfluidic region (or signal/ground microfluidic sections) 412. The pair of pad regions 408 include a first CPW port and a second CPW port that provide a coupling to a vector network analyzer (VNA) through probes known as ground-signal-ground (GSG) probes. In one example embodiment, the pair of pad regions 408 may be configured for coupling to 100-μm pitch GSG probes. In addition, the characteristic impedance (e.g., 50Ω) of the CPW transmission line 400 at the pair pad regions 408, in one example embodiment, may be configured to match an impedance of the GSG probes.
The pair of taper regions 410 connect the pair of pad regions 408 to opposite ends of the microfluidic region 412. Referring to
Similarly, a width w2 of the ground conductors 404 also varies in the taper region 410 between the pad region 408 and the microfluidic region 412. Specifically, the width w2 increases from the pad region 408 to the microfluidic region 412 (or decreases from the microfluidic region 412 to the pad region 408), which is defined by a ground conductor taper angle β. The ground conductor taper angle β, however, is not equal to the signal conductor taper angle α. In other words, the width w2 of the ground conductors increases/decreases at an angle that is different than the angle of increase/decrease of the width w1 of the signal conductor 402. As a result, a width w3 of each continuous gap 406 decreases from the pad region 408 to the microfluidic region 412 (or increases from the microfluidic region 412 to the pad region 408).
Still referring to
The microfluidic region 412 is a narrow section that runs directly over a top of the channels 202. The microfluidic region 412 is narrower than the pad regions 408, which maximizes the interaction between electric fields of the CPW transmission line 400 and the channels 202. This primarily occurs in the gaps 406 between the signal conductor 402 and the two ground conductors 404.
More specifically, the signal conductor 402 has a width w4 (e.g., 50-100 μm) in the pad region 408 and a width w5 (e.g., 14-28 μm) in the microfluidic region 412 where w4 is greater than w5. More specifically, the width w5 of the signal microfluidic section 412 is less than half of the width w4 of the signal pad section 408. The ground conductors 404 have a width w6 (e.g., 124-152 μm) in the pad region 408 and a width w7 (e.g., 162-171 μm) in the microfluidic region 412 where w6 is less than w7. As mentioned above, the width w1, w2 of both the signal and ground conductors 402, 404 respectively varies between the pad region 408 and the microfluidic region 412. It is to be understood that width of the signal and ground conductors 402, 404 in the regions 408, 410, 412 may be any value (including values outside the example ranges provided above) based on parameters, such as but not limited to the type of application the microfluidic chip 100 may be used in.
In addition, the continuous gaps 406 have a width w8 in the pad region 408 and a width w9 in the microfluidic region 412 where w8 is greater than w9. For example, in one embodiment the width w8 in the pad region 408 may be as little as 3 μm to as much as 6 μm and the width w9 of the gap 406 in the microfluidic region 412 may be a little as 2 μm and as much as 4 μm. Thus, in this example embodiment, since the width w3 of the continuous gaps 406 varies in the taper region 410, the width w3 of the continuous gap 406 may decrease from 3 μm at the pad region 408 to 2 μm at the microfluidic region 412 or from 6 μm at the pad region to 4 μm at the microfluidic region 412. It is to be understood that width of the gaps 406 in the regions 408, 410, 412 may be any value based on parameters, such as but not limited to the type of application the microfluidic chip 100 may be used in.
Regarding the electric fields 550, assuming that the CPW transmission line 400 is propagating only its “even” mode, whereby a plane of antisymmetry 560 exists through a geometric center 570 of the CPW transmission line 400, then for an x-y coordinate system as shown in
The effect of the channels 202 can be represented by their geometry and by the dielectric constant of the solution filling them. Assuming the channels 202 are uniformly filled, the “effective” dielectric ∈S of the substrate in the presence of the microfluidic channels 202 will display symmetry with respect to the same plane, i.e., ∈S(x)=∈S(−x). And because ∈S is a scalar quantity, its symmetry is consistent with the antisymmetry of the electric field 550 of the CPW transmission line 400 even mode. In other words, the microchannel region will not scatter the even mode, or transform it to other possible propagating modes, such as the odd mode. The microchannel region 200, however, can readily induce the absorption of propagating radiation, especially with the channels 202 full of aqueous solution.
An Effective-Media Analysis can be performed to predict and confirm this effect.
An aqueous solution will change ∈S, and to predict that effect the Maxwell-Garnett model of effective-media theory is utilized where the expression for the effective dielectric constant is:
where ∈B and ∈I are the dielectric functions of the background host and inclusion, respectively, fI is the volumetric fill factor of the inclusion, and Ni is a depolarization factor of the inclusion taken along three orthogonal axes. The dielectric function of PDMS has at least for frequencies below 100 GHz, ∈B is primarily real. For example, at 77 GHz, ∈B≈2.67, and tan δ≈0.04, where tan δ is the dielectric loss tangent defined by tan δ≡Im{∈}/Re{∈} in non-conducting material. Henceforth, we will assume ∈B is real and =2.67.
The depolarization factor requires further investigation. For example, an infinite cylinder whose axis is aligned along the i=1 (x axis) of
Next, an estimate of the dielectric function, ∈I, of the aqueous solution is required. Assuming that like most biological solutions, the pH is close to neutral and the salinity is low. Under those conditions, the dielectric function of an aqueous solution from RF-to-THz frequencies is adequately described by the double-Debye model:
where ∈0 is the dc value of 79.7, ∈∞ is the infinite-frequency value of 3.37, and ∈1 is the intermediate value of 5.35. The other key parameters in this model are the relaxation frequencies, v1=20.7 GHz, and v2=692 GHz. These are inversely related to characteristic relaxation times, τ1=7.7 ps, and τ2=0.23 ps. The resulting curves for the real and imaginary parts of ∈w are plotted in the graph 600 shown in
To complete the effective-medium analysis of the microfluidic region 412, a fill factor of the channels 202 relative to the substrate 500 must be estimated. The estimation entails both volumetric and electric-field-strength effects. However, referring to
Whether in a homogeneous or composite medium, the attenuation coefficient cc can be calculated from the real and imaginary parts of the effective dielectric constant by introduction of the complex refractive index, n=(∈)1/2. Then
α=2*Imag{n}*k (4)
where k=ω/c is the propagation constant where c is the speed of light in vacuum. A plot 800 of α is shown in
The attenuation length is plotted in the graph 900 shown in
Given ample availability, L then serves as a maximum length for which the background attenuation will be −4.3 dB, which is an acceptable loss (“insertion loss” in microwave-engineering jargon). However, as seen in
The microchannel region 1200 includes microfluidic channels 1202, reservoirs 1204 having a top surface 1206, and fill ports 1208. The channels 1202 run substantially parallel between the reservoirs 1204 where the reservoirs 1204 supply an aqueous solution to the channels 1202. The fill ports 1208 extend upward from the top surface 1206 of each reservoir 1204 and are exposed from the superstrate 1300 such that the aqueous solution can be provided to the reservoirs 1204 via the fill ports 1208. Thus, a top surface 1210 of each fill port 1208 may be flush with the top surface 1302 of the superstrate 1300 or may extend above the top surface 1302 of the superstrate 1300.
Still referring to
The dielectric environment of the CPW transmission line 1400 is different in the SS structure than in the substrate only structure described above. This is quantified by the effective dielectric constant ∈eff. Most electromagnetic computer-aided design (CAD) tools for coplanar transmission lines assume a half-space of air above the substrate, so they work very well for the launching regions (the end of the transmission lines shown in
∈ff,SS≈(∈sub+∈sup)/2 (5)
and the fundamental mode velocity is given by
v
ss
≈c/(∈eff)1/2 (6)
where c is the speed of light in vacuum.
The critical design issue in the SS structure is to make the transmission-line characteristic impedance Z0,SS, match the characteristic impedance in the substrate-only region, Z0 (e.g., approximately 50 Ohms). An equivalent-circuit representation of lossless transmission line is utilized whereby the electromagnetic-wave behavior can be represented by a series specific inductance L′ (inductance per unit length) and a shunt specific capacitance C′ (capacitance per unit length). With these circuit parameters the following can be written:
v≈1/(L′C′)1/2 (7)
Z
o≈(L′/C′)1/2 (8)
These relationships are exact for TEM-type transmission lines (e.g., coaxial), but are acceptably accurate for quasi-TEM lines such as the coplanar types used for the present invention.
The dimensions of the coplanar line for which Z0,SS≈50 Ohms can be found by an equivalence method which assumes a fictitious coplanar line having the same dimensions as the SS line but on an insulating half-space of the substrate alone. Because the metal dimensions are the same and there are no magnetic materials anywhere, the specific inductance of the fictitious line will be the same as for the substrate-superstrate line, L′SS. By taking the ratio of Eq. (8) to Eq. (7), C′ is canceled and get the useful relationship:
L′=Z
0
/v (9)
We set this in turn to the specific inductance of the actual substrate-superstrate structure and the fictitious structure, getting the relation:
Z
0,F
/v
F
=Z
0,SS
/v
ss (10)
Although less accurate than Eq. (5), we can approximate the effective dielectric constant of the fictitious line as
∈eff,F≈(∈sub+1)/2 (11)
and the fundamental mode velocity as
v
ss,F
≈c/(∈eff,F)1/2 (12)
Substitution of Eq. (6) and Eq. (12) into Eq. (10) then yields a design expression,
Z
0,F
=Z
0,SS[(∈sub+∈sup)/(∈sub+1)]1/2≡50·[(∈sub+∈sup)/(∈sub+1)]1/2 (13)
Knowing ∈sub and ∈sup, a transmission-line design tool can be used to get the dimensions of the fictitious line, and those will be the same dimensions that achieve 50 Ohm in the SS structure.
In an example embodiment,
Referring to
As mentioned above, the radiative interrogation of the innovative microfluidic chip 100 can be done in such a way that a unique signature appears in the transmittance vs. frequency graph illustrated in
Another advantage is autonomy. With a signature-to-noise ratio as shown in
Another advantage is that the innovation is safer than existing technology from a biological threat standpoint. The innovation allows for the detection of molecules or particles at their in-situ concentration levels, expected to be parts-per-billion at locations where human-health is affected. On the other hand, existing technology, especially PCR, must multiply the genomic matter roughly one-million fold, thereby creating concentrations that could be lethal in the event of a leakage. Further, the innovation can analyze samples inside polyethylene sample bags without exposing workers to the agents.
One market for the innovation could be the Departments of Defense and Homeland Security. Other applications and uses can include the monitoring of live viruses in public places and likely areas of proliferation, such as hospitals, nursing homes, airports, train stations, etc. The application would likely entail swabbing certain items such as bathroom door handles, check-in counter tops, etc. that are subject to continuous human handling. The swab contents would then be transferred to the reservoir of the microfluidic chip, and the chip would be loaded into the RF analyzer for interrogation. Other sample collection devices could include air and water filters. Many different viral species could be detected, with sensitivity levels that depend on the strength of each vibrational signature. In addition, the innovation can be easily modified to accommodate different applications, uses, sample collection considerations, etc.
What has been described above includes examples of the innovation. It is, of course, not possible to describe every conceivable combination of components or methodologies for purposes of describing the subject innovation, but one of ordinary skill in the art may recognize that many further combinations and permutations of the innovation are possible. Accordingly, the innovation is intended to embrace all such alterations, modifications and variations that fall within the spirit and scope of the appended claims. Furthermore, to the extent that the term “includes” is used in either the detailed description or the claims, such term is intended to be inclusive in a manner similar to the term “comprising” as “comprising” is interpreted when employed as a transitional word in a claim.
This application claims the benefit of U.S. Provisional Patent Application Ser. No. 62/025,736 entitled “A TRANSMISSION-LINE-COUPLED MICRO-FLUIDIC-CHIP TECHNOLOGY FOR ELECTROMAGNETIC SENSING OF BIOMOLECULES AND BIOPARTICLES” filed on Jul. 17, 2014. The entirety of the above-noted application is incorporated herein by reference.
Number | Date | Country | |
---|---|---|---|
62025736 | Jul 2014 | US |